

TEST CHANGE

Borrelia burgdorferi Antibodies, IgG and IgM by Immunoblot (CSF)

0055260, LYME WBCSF

Specimen Requirements:

Patient Preparation:

Collect: CSF.

Specimen Preparation: Transfer 3 mL CSF to an ARUP Standard Transport Tube. (Min:

2 mL)

Transport Temperature: Refrigerated.

Unacceptable Conditions: Bacterially contaminated, heat-inactivated, hemolyzed, or

xanthochromic specimens.

Remarks:

Stability: Ambient: 8 hours; Refrigerated: 2 weeks; Frozen: 1 year (avoid

repeated freeze/thaw cycles)

Methodology: Qualitative Immunoblot

Performed: Sun-Sat

Reported: 1-43 days

Note: A negative result indicates that the immunoblot evaluation for

B. burgdorferi antibody demonstrates no antibodies unique to B. burgdorferi and is, therefore not supportive of Lyme disease. A positive result indicates that the immunoblot evaluation for Lyme antibody is consistent with the presence of antibody produced by patients in response to infection by B. burgdorferi and suggests the presence of Lyme disease. Although the test has been shown to have a high degree of reliability for diagnostic purposes, laboratory data should always be correlated with clinical findings. Current CDC recommendations for the serological diagnosis of Lyme disease are to screen with a polyvalent ELISA test and confirm equivocals and positives with immunoblot. Both IgM and IgG

Effective Date: May 15, 2023

equivocals and positives with immunoblot. Both IgM and IgG immunoblots should be performed on samples obtained less than 4 weeks after appearance of erythema migrans. Only IgG immunoblot is to be performed on samples greater than 4 weeks after disease onset. IgM immunoblot in the chronic stage is not recommended and does not aid in the diagnosis of

neuroborreliosis or chronic Lyme disease.

CPT Codes: 86617 x2

New York DOH Approval Status: Specimens from New York clients will be sent out to a New

York DOH approved laboratory, if possible.

Effective Date: May 15, 2023

Interpretive Data:

IgG: For this assay, a positive result is reported when any 5 or more of the following 10 bands are present: 18, 23, 28, 30, 39, 41, 45, 58, 66, or 93 kDa. All other banding patterns are reported as negative.

IgM: For this assay, a positive result is reported when any 2 or more of the following bands are present: 23, 39, or 41 kDa. All other banding patterns are reported as negative.

The detection of antibodies to *Borrelia burgdorferi* in cerebrospinal fluid may indicate central nervous system infection. However, consideration must be given to possible contamination by blood or transfer of serum antibodies across the blood-brain barrier.

This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the US Food and Drug Administration. This test was performed in a CLIA certified laboratory and is intended for clinical purposes.

Reference Interval:

Effective August 15, 2011

Negative